Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

591.65INR
10:16am GMT
Change (% chg)

Rs15.20 (+2.64%)
Prev Close
Rs576.45
Open
Rs578.40
Day's High
Rs594.90
Day's Low
Rs571.65
Volume
2,379,562
Avg. Vol
1,493,459
52-wk High
Rs663.40
52-wk Low
Rs480.20

Select another date:

Thu, Nov 30 2017

BRIEF-Cipla Launches Q-Tib Globally

* SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION

BRIEF-Cipla gets final approval for generic Dacogen​

* Drug indicated for treatment of patients with myelodysplastic syndromes

Yes Bank, IndusInd to join India's BSE Sensex index; Lupin, Cipla dropped

Nov 17 Indian private sector lenders Yes Bank Ltd and IndusInd Bank Ltd will join the BSE stock exchange's 30-member Sensex index, effective Dec. 18, the index provider said on Friday.

BRIEF-Cipla gets final approval for generic Pulmicort Respules

* Cipla receives final approval for generic Pulmicort Respules

UPDATE 1-India's Cipla Q2 profit up 19 pct on higher domestic sales

Nov 7 Cipla Ltd, India's second largest drugmaker by market capitalisation, posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.

India's Cipla Q2 profit rises 19 pct

Nov 7 Cipla Ltd, India's second largest drugmaker by market capitalisation, posted a 19 percent rise in quarterly profit, slightly above analysts' estimate.

BRIEF-India's Cipla Sept qtr consol profit up about 19 pct

* Sept quarter consol net profit 4.23 billion rupees versus profit of 3.54 billion rupees last year

BRIEF-Cipla's U.S. unit gets final FDA nod for generic Renvela tablets

* Says co's U.S. unit gets final FDA nod for generic Renvela tablets ‍​ Source text: http://bit.ly/2yQhj02 Further company coverage:

UPDATE 1-India's Cipla Q1 profit rises 20 pct, beats estimates

* South Africa revenue up 21 pct (Adds details from press release)

India's Cipla June-qtr profit rises 20 pct, beats estimates

Aug 11 Cipla Ltd, India's fourth-largest drugmaker by sales, reported a 20 percent rise in quarterly profit, beating analysts' estimates.

Select another date: